Inclusion Criteria:

• * Any self-declared ethnicity-race
• * Open-angle with one of the following:
• 1. Untreated OHT ≥ 21mmHg
• 2. Treated OHT with history of IOP ≥ 21 mmHg on 2 prior clinic visits or IOP ≥ 21 mmHg at screening
• 3. Mild-to-moderate stage open-angle glaucoma based on history of untreated IOP ≥ 21 mmHg
• * Reliable Humphrey visual field test result within previous 1 year
• * Open on gonioscopy within previous 1 year
• * At least one eye must be phakic
• * Able to cooperate for aqueous humor dynamic procedures
• * Able to participate on site over the multi-visit study period
• * Contact lenses must be removed before topical fluorescein instillation and remain out until study testing the following day is completed.
• * Contact lenses must be removed for the entire duration of the study visits.
• * All study medication must be used without contact lenses in the eyes.

Exclusion Criteria:

• * Women who are pregnant or breastfeeding
• * IOP ≥ 38 in study eye(s) or at discretion of the clinician
• * Refusal to remove contact lenses
• * Advanced visual field loss (MD ≤ -16 dB) or threat to fixation in study eye(s) or at discretion of the clinician
• * Study eye(s) with any sign of Fuchs cornea dystrophy as noted clinically with guttae and corneal edema
• * Narrow angle of ≤ Shaffer grade 2 for 180 degrees, peripheral synechiae, or peripheral iridotomy in either eye
• * History of acute angle closure crisis in either eye
• * History of glaucoma incisional surgery (e.g., trabeculectomy, glaucoma drainage implant, Xen gel stent) in study eye(s)
• * History of minimally invasive glaucoma surgery (MIGS, e.g., angle surgery, Cypass) in study eye(s)
• * History of any cycloablation surgery (e.g., micropulse or diode transcleral or endoscopic cyclophotocoagulation) in study eye(s)
• * Study eye cannot have history of any past SLT or ALT glaucoma laser treatments.
• * Study eye(s) cannot have any history of refractive surgery
• * Study eye(s) cannot have any history of herpetic infection of the cornea
• * Study eye(s) cannot have chronic or recurrent inflammatory eye disease
• * Study eye(s) cannot have ocular trauma within the past 6 months, other than uncomplicated cornea abrasion
• * Study eye(s) cannot have ocular infection in the past 3 months
• * Study eye(s) cannot have clinically significant retinal disease that includes proliferative diabetic retinopathy, vein occlusion, cystoid macular edema, wet age-related macular degeneration
• * History of intraocular or peri-ocular injections in study eye(s) within 3 months
• * History of oral steroid use within 30 days of screening Visit 1
• * Any abnormality preventing reliable fluorophotometry (e.g., corneal scarring or severe dry eye with fluorescein staining)
• * Serious hypersensitivity to any components of study medications or risk from treatment (e.g., sulfa drug allergy, bradycardia, severe asthma, or emphysema)
• * Participants must be on minimum 30-day stable regimen prior to Visit 1 for a systemic medication that may affect IOP (i.e., sympathomimetics, beta-blockers, alpha-adrenergic agonists and blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, etc.). Any change of such medication during the study will result in exclusion.
• * Prohibited meds during study: cannabis products, brimonidine 0.025% (Lumify), bimatoprost 0.03% for eyelash growth (Latisse), topical ocular and peri-ocular steroids, oral steroids